Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab von Manneh Kopp, R. A., Sepúlveda-Sánchez, J. M., Ruano, Y., Toldos, O., Pérez Núñez, A., Cantero, D., Hilario, A., Ramos, A., de Velasco, G., Sánchez-Gómez, P., Hernández-Laín, A.

Volltext

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma von Choueiri, Toni K., Powles, Thomas, Peltola, Katriina, de Velasco, Guillermo, Burotto, Mauricio, Suarez, Cristina, Ghatalia, Pooja, Iacovelli, Roberto, Lam, Elaine T., Verzoni, Elena, Gümüş, Mahmut, Stadler, Walter M., Kollmannsberger, Christian, Melichar, Bohuslav, Venugopal, Balaji, Gross-Goupil, Marine, Poprach, Alexandr, De Santis, Maria, Schutz, Fabio A., Park, Se Hoon, Nosov, Dmitry A., Porta, Camillo, Lee, Jae Lyun, Garcia-del-Muro, Xavier, Biscaldi, Elisa, Manneh Kopp, Ray, Oya, Mototsugu, He, Li, Wang, Aobo, Perini, Rodolfo F., Vickery, Donna, Albiges, Laurence, Rini, Brian

Volltext

1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomiz... von Gratzke, C.J., Ozguroglu, M., Peer, A., Sendur, M.A.N., Retz, M., Goh, J.C.H., Loidl, W.C., Jayram, G., Byun, S-S., Kwak, C., Kwiatkowski, M., Manneh Kopp, R., Vazquez Limon, J.C., Escobar Penagos, J.F., De Giorgi, U.F.F., Trindade, K.M.D., Niu, C., Liu, Y., Poehlein, C.H., Piulats Rodriguez, J.M.

Volltext

Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (p... von Hernando Cubero, J., Grande, E., Castellano Gauna, D., Ibrahim, T., Fazio, N., Lopez, C., Teulé, A., Valle, J.W., Alonso, V., Molina-Cerrillo, J., Tafuto, S., Custodio, A., Trejo, L., Casteras, A., Manneh Kopp, R., Miqueo, C., Roca Herrera, M., Garcia-Carbonero, R., Salazar, R., Capdevila, J.

Volltext

46P BASAL (PRE-TREATMENT) PET SCAN [MAXIMUM STANDARDIZED UPTAKE VALUES (SUVMAX)] AS A PROGNOSTIC FACTOR IN SMALL CELL LUNG CANCER PATIENTS WITH EXTENDED DISEASE von Aix, S. Ponce, Kopp, R. Manneh, Rubio, L. Parrilla, Docampo, L. Iglesias, Solis, S. Ruiz, Nuñez, J.A, Martinez, T. Pascual

Volltext